Recurrent spontaneous pneumothorax under nintedanib treatment in ınterstitial lung disease associated with systemic sclerosis

Sarcoidosis Vasc Diffuse Lung Dis. 2023 Dec 20;40(4):e2023044. doi: 10.36141/svdld.v40i4.14716.ABSTRACTInterstitial lung disease (ILD) is a common complication that can develop during the course of systemic sclerosis (SSc). Nindetanib is an antifibrotic drug approved for the treatment of systemic sclerosis-associated interstitial lung disease. Although there is an insufficient data on the development of pneumothorax, the safety of Nintedanib treatment is also uncertain. We observed recurrent resistant pneumothorax under nintedanib treatment in a patient with systemic sclerosis-associated interstitial lung disease. Nintedanib use may increase the risk of developing refractory pneumothorax. Ssc patients who are started on nintedanib should be followed carefully for pneumothorax.PMID:38126501 | PMC:PMC10965007 | DOI:10.36141/svdld.v40i4.14716

Source: Sarcoidosis Vasculitis and Diffuse Lung Diseases - December 21, 2023 Category: Respiratory Medicine Authors: Abdurrahman Soner Şenel Tu ğba Kahraman Denizhan Melih K ızıltepe Emel O ğuz Kökoğlu Nuri Tutar Source Type: research